1. COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets

   News item 24 April 2021 Pages: 1 - 1

2. Denmark ceases roll out of AstraZeneca's COVID-19 vaccine

   News item 24 April 2021 Pages: 2 - 2

3. FDA remote evaluation of drug manufacturing during COVID-19

   News item 24 April 2021 Pages: 3 - 3

4. Health Canada: AKI or ARF with remdesivir for COVID-19?

   News item 24 April 2021 Pages: 4 - 4

5. Health Canada: blood clots with AstraZeneca's COVID-19 vaccine

   News item 24 April 2021 Pages: 5 - 5

6. Medsafe provides bupropion update after monitoring completion

   News item 24 April 2021 Pages: 6 - 6

7. PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines

   News item 24 April 2021 Pages: 7 - 7

8. Use of Eylea pre-filled syringe increases risk of ocular hypertension

   News item 24 April 2021 Pages: 8 - 8

9. Anti-PD-1-induced cardiac events in patients with melanoma

   Clinical study 24 April 2021 Pages: 9 - 9

10. Daratumumab reactivates resolved HBV in patients with multiple myeloma

    Clinical study 24 April 2021 Pages: 10 - 10

11. Five drugs account for over 50% of deaths due to DRESS syndrome

    Clinical study 24 April 2021 Pages: 11 - 11

12. Medication-related safety incidents in paediatric ICUs

    Clinical study 24 April 2021 Pages: 12 - 12

13. Other adverse reaction research

    News item 24 April 2021 Pages: 13 - 13

14. Abatacept

    Case report 24 April 2021 Pages: 14 - 14

15. Abatacept/corticosteroids/rituximab

    Case report 24 April 2021 Pages: 15 - 15

16. Abciximab

    Case report 24 April 2021 Pages: 16 - 16

17. Acetazolamide

    Case report 24 April 2021 Pages: 17 - 17

18. Acetazolamide

    Case report 24 April 2021 Pages: 18 - 18

19. Acetyl-hexapeptide-8/clarithromycin/minocycline

    Case report 24 April 2021 Pages: 19 - 19

20. Adalimumab/Apremilast

    Case report 24 April 2021 Pages: 20 - 20

21. Adalimumab/etanercept

    Case report 24 April 2021 Pages: 21 - 21

22. Adalimumab/infliximab/mesalazine

    Case report 24 April 2021 Pages: 22 - 22

23. Adalimumab/prednisolone

    Case report 24 April 2021 Pages: 23 - 23

24. Adefovir

    Case report 24 April 2021 Pages: 24 - 24

25. Adenosine/diltiazem/tirofiban

    Case report 24 April 2021 Pages: 25 - 25

26. Aflibercept

    Case report 24 April 2021 Pages: 26 - 26

27. Albumin human/heparin/methylprednisolone

    Case report 24 April 2021 Pages: 27 - 27

28. Amfetamine/methylphenidate/modafinil

    Case report 24 April 2021 Pages: 28 - 28

29. Amikacin/dexlansoprazole

    Case report 24 April 2021 Pages: 29 - 29

30. Aminolevulinic-acid

    Case report 24 April 2021 Pages: 30 - 30

31. Amiodarone

    Case report 24 April 2021 Pages: 31 - 31

32. Amiodarone/dobutamine/sotalol

    Case report 24 April 2021 Pages: 32 - 32

33. Amiodarone/pembrolizumab

    Case report 24 April 2021 Pages: 33 - 33

34. Amiodarone/phenytoin/thalidomide

    Case report 24 April 2021 Pages: 34 - 34

35. Amitriptyline overdose

    Case report 24 April 2021 Pages: 35 - 35

36. Amitriptyline/gabapentin

    Case report 24 April 2021 Pages: 36 - 36

37. Amoxicillin

    Case report 24 April 2021 Pages: 37 - 37

38. Amphotericin B

    Case report 24 April 2021 Pages: 38 - 38

39. Anaesthetics

    Case report 24 April 2021 Pages: 39 - 39

40. Anaesthetics/antiepileptic drugs/benzodiazepines

    Case report 24 April 2021 Pages: 40 - 40

41. Analgesics

    Case report 24 April 2021 Pages: 41 - 41

42. Anti-inflammatories

    Case report 24 April 2021 Pages: 42 - 42

43. Antibacterials

    Case report 24 April 2021 Pages: 43 - 43

44. Antiepileptic drugs

    Case report 24 April 2021 Pages: 44 - 44

45. Antiepileptic-drugs

    Case report 24 April 2021 Pages: 45 - 45

46. Antiepileptic-drugs

    Case report 24 April 2021 Pages: 46 - 46

47. Antihypertensives

    Case report 24 April 2021 Pages: 47 - 47

48. Antineoplastics

    Case report 24 April 2021 Pages: 48 - 48

49. Antineoplastics

    Case report 24 April 2021 Pages: 49 - 49

50. Antineoplastics

    Case report 24 April 2021 Pages: 50 - 50